Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Risperidone is a second-generation (atypical) antipsychotic medication used primarily to treat schizophrenia, bipolar disorder (including acute manic or mixed episodes and maintenance therapy), and irritability associated with autism spectrum disorder. It acts by modulating the activity of neurotransmitters in the brain, particularly dopamine and serotonin, thereby improving symptoms such as hallucinations, delusions, mood disturbances, aggression, and behavioral problems. Developed originally by Janssen (now part of Johnson & Johnson), risperidone is available in multiple formulations including oral tablets, orally disintegrating tablets, oral solution, and long-acting injectable forms[1][2][3][4][5][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on risperidone.